SciELO - Scientific Electronic Library Online

vol.33 número2El vértigo y su relación con el síndrome metabólicoInhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay artículos similaresSimilares en SciELO


Medicina interna de México

versión impresa ISSN 0186-4866


VALDES-SOLIS, E  y  LOZANO-NUEVO, JJ. Inflammation and metabolic syndrome due to insulin-leptin resistance in psoriatic patients. Med. interna Méx. [online]. 2017, vol.33, n.2, pp.218-225. ISSN 0186-4866.

Psoriasis is a chronic inflammatory disease characterized by relapsing skin hyperproliferation, with multifactorial pathogenesis and causes. It affects approximately 1% to 3% of the general population. During the past ten years, several studies have found that patients with psoriasis have a high prevalence of cardiovascular risk factors. Likewise, such studies also suggest a link between metabolic syndrome and psoriasis. Metabolic syndrome comprises a number of pathophysiologic conditions that mainly involves the metabolic aspects concerning insulin-leptin resistance and signaling (Sx Met_RI-Lep). It is a group of risk factors including central obesity, atherogenic dyslipidemia, systemic hypertension and glucose intolerance. Its importance is due to its presence doubles the risk of cardiovascular disease, type 2 diabetes mellitus and increases mortality higher than its separate components. The worldwide prevalence of the syndrome varies depending on the country and the criteria used; between 15% and 47% of the general population. The prevalence published also vary according to the organizations that issue; such is the case of the criteria of the World Health Organization (WHO) to handle a prevalence in Mexico of 14% and applying the criteria ATP-III rises to 27%, so there are 6.7 and 14.3 million Mexicans affected, according to the criteria of the World Health Organization and the ATP-III, respectively. The association of psoriasis with other systemic diseases may be due to various causes such as genetic predisposition, environmental factors (smoking, alcohol, sedentary lifestyle) or be influenced by systemic treatments used against psoriasis. More and more studies link the Sx Met_RI-Lep with psoriasis. This paper summarizes the pathophysiological mechanisms shared by both pathologies, as well as emphasizes screening for cardiovascular risk factors and metabolic syndrome to improve treatment and prognosis of psoriasis.

Palabras llave : insulin-leptin resistance; psoriasis; metabolic syndrome.

        · resumen en Español     · texto en Español     · Español ( pdf )